Trials / Not Yet Recruiting
Not Yet RecruitingNCT07420855
International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC
International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced/Metastatic Urothelial Cancer (ARON-2PLUS)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 361 (estimated)
- Sponsor
- Aron Research Foundation Ets · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.
Conditions
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2026-11-01
- Completion
- 2030-12-01
- First posted
- 2026-02-19
- Last updated
- 2026-02-19
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT07420855. Inclusion in this directory is not an endorsement.